Elicit: Secukinumab and IL-17A: Cytokine Modulation Evidence
Secukinumab IL-17A receptor interaction: what evidence supports downstream cytokine reduction?
Evidence supporting downstream cytokine reduction includes
- Rapid temporal correlation between IL-17A neutralization and suppression of IL-17-dependent mediators.
- Quantitative reductions in cytokines and inflammatory biomarkers.
- Pathway-specific effects with preserved immune function.
- Cellular changes including neutrophil clearance and tissue normalization.
- Dose-response relationships.
Abstract
Secukinumab, a fully human monoclonal antibody, selectively binds and neutralizes IL-17A. Evidence supporting downstream cytokine reduction includes:
- Rapid suppression of the IL-23/IL-17 axis beginning at Week 1.
- Concurrent reductions in IL-17-dependent mediators such as beta-defensin2, CXCL1, and CXCL8.
- Quantitative reductions like IL-6 decreases up to 38.4%, CRP reductions of 35.3%, and IL-17A declines of 42-68% over 52 weeks.
- Cellular evidence includes rapid neutrophil clearance and normalization of keratinocyte function.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Records from Elicit search
- n = 200
- Papers screened using:
- Human Participants with Secukinumab.
- Cytokine/Inflammatory Marker Measurement.
- Comparative or Longitudinal Design.
- Appropriate Patient Population.
- Acceptable Study Design.
- Human Study Focus.
- Secukinumab Inclusion.
- Adequate Sample Size.
Screening Results
- Papers screened out: n = 190
- Papers included for extraction: n = 10
Results
Characteristics of Included Studies
- Identified 10 studies evaluating secukinumab’s mechanism of action and downstream effects on cytokine reduction.
- Studies varied in design, sample size, duration, and full text availability.
Study Summary
| Study | Full text retrieved? | Study design | Primary focus | Sample size | Duration |
|---|---|---|---|---|---|
| J. Krueger et al., 2023 | Yes | Randomized controlled trial (RCT) | Clinical efficacy and mechanism | 40 patients | 16 weeks |
| K. Akhmedov et al., 2025 | No | Prospective observational study | Clinical efficacy and disease activity | 184 patients | 52 weeks |
| J. Merola et al., 2022 | Yes | Post hoc analysis of pooled trials | Cardiovascular risk factors | 9,197 patients from 19 trials | At least 1 year |
| J. Krueger et al., 2019 | Yes | Randomized controlled trial (RCT) | Clinical efficacy and mechanism | Study population measured at multiple timepoints | 12 weeks |
| P. Mease et al., 2015 | No | Randomized controlled trial (RCT) | Clinical efficacy | 606 patients | 52 weeks |
| G. Bruin et al., 2019 | Yes | Open-label study | Mechanistic study | 24 patients | Multiple assessments over time |
| K. Reich et al., 2015 | Yes | Randomized controlled trial (RCT) | Clinical efficacy | 100 subjects | 12 weeks induction, follow-up to Week 56 |
| I. McInnes et al., 2013 | Yes | Randomized controlled trial (RCT) | Clinical efficacy and safety | 42 patients | 24 weeks |
| M. Genovese et al., 2012 | No | Randomized controlled trial (RCT) | Clinical efficacy and safety | 237 patients | 16 weeks |
| M. Sande et al., 2018 | No | Open-label trial | Mechanism of action | 20 patients | 12 weeks |
Evidence of IL-17A Receptor Interaction
Studies evaluated secukinumab’s mechanism through multiple approaches, though most inferred receptor interaction from downstream effects. Secukinumab selectively inhibits IL-17A, preventing it from binding to its receptor and triggering downstream inflammatory cascades.
Downstream Cytokine and Biomarker Reduction
Studies documented reductions in inflammatory mediators following secukinumab treatment, varying in the specific cytokines measured
- Study: J. Krueger et al., 2023
- Cytokines/Biomarkers Measured: CRP, IL-6
- Quantitative Changes: Reduction in serum levels
- Measurement Location: Serum
- Methods: RNASeq, qRT-PCR
Temporal Correlation Between IL-17A Inhibition and Cytokine Reduction
The timeline of cytokine reduction indicated early effects across multiple studies, showing that by Week 2, significant reductions appeared. Suppression of the IL-23/IL-17 axis began at Week 1 and continued through Week 12.
Supporting Biological Evidence
Studies showed cellular, histological, and functional changes supporting the IL-17A receptor-mediated mechanism, observable through significant improvements in the normalization of keratinocyte function.
Conclusion
The evidence across the analyzed studies indicates that secukinumab does not alter traditional cardiovascular risk factors while significantly reducing hsCRP and NLR. Future studies should explore direct receptor binding to strengthen the mechanistic understanding.